Abstract
The Health and Environmental Sciences Institute (HESI) Developmental and Reproductive Toxicology Technical Committee sponsored a pharmaceutical industry survey on current industry practices for contraception use during clinical trials. The objectives of the survey were to improve our understanding of the current industry practices for contraception requirements in clinical trials, the governance processes set up to promote consistency and/or compliance with contraception requirements, and the effectiveness of current contraception practices in preventing pregnancies during clinical trials. Opportunities for improvements in current practices were also considered. The survey results from 12 pharmaceutical companies identified significant variability among companies with regard to contraception practices and governance during clinical trials. This variability was due primarily to differences in definitions, areas of scientific uncertainty or misunderstanding, and differences in company approaches to enrollment in clinical trials. The survey also revealed that few companies collected data in a manner that would allow a retrospective understanding of the reasons for failure of birth control during clinical trials. In this article, suggestions are made for topics where regulatory guidance or scientific publications could facilitate best practice. These include provisions for a pragmatic definition of women of childbearing potential, guidance on how animal data can influence the requirements for male and female birth control, evidence-based guidance on birth control and pregnancy testing regimes suitable for low- and high-risk situations, plus practical methods to ascertain the risk of drug-drug interactions with hormonal contraceptives.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
ICH. ICH Harmonized Tripartite Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials for the Conduct of Human Trials and Marketing Authorization for Pharmaceuticals M3(R2). 2009.
UK MHRA. Clarification of contraceptive wording in clinical trials (version 2, amended 21 May 2010). 2010.
Ng EW, Chiruvolu P, Levy GF, Allan BR, Wyszynski DF. Contraception language in informed consent forms: a survey of biopharmaceutical companies. Drug Inform J. 2012;46:329–335.
UK MHRA. Recommendations related to contraception and pregnancy testing in clinical trials. Advisory non-binding guidance supported by national competent authorities represented at the CTFG-meeting in Rome 2014-09-15. 2014.
World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. Geneva: Department of Reproductive Health, WHO; 2010.
Chen CL, Beyer BK, Breslin WJ, et al. Introduction to the HESI DART Drugs in Semen Consortium. Reprod Toxicol. 2014;48:113–114.
Hui JY, Hoffmann M, Kumar G. Embryo-fetal exposure and developmental outcome of thalidomide following oral and intravaginal administration to pregnant rabbits. Reprod Toxicol. 2014;48:115–123.
Breslin WJ, Hilbish KG, Page TJ, Coutant DE. Assessment of fetal exposure risk following seminal excretion of a therapeutic IgG4 (T-IgG4) monoclonal antibody using a rabbit model. Reprod Toxicol. 2014;48:124–131.
Moffat GJ, Davies R, Kwon G, et al. Investigation of maternal and fetal exposure to an IgG2 monoclonal antibody following biweekly intravaginal administration to cynomolgus monkeys throughout pregnancy. Reprod Toxicol. 2014;48:132–137.
Cao J, Ying X, Beyer BK, DeLise AM. The use of optical imaging to assess the potential for embryo-fetal exposure to an exogenous material after intravaginal administration. Reprod Toxicol. 2014;48:138–147.
Westhoff C, Davis A. Tubal sterilization: focus on the U.S. experience. Fertil Steril. 2000;73:913–922.
ICH. ICH Harmonized Tripartite Guideline: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1). 2011.
Silverman M, Sheffer A, Diaz PV, et al. Outcome of pregnancy in a randomized controlled study of patients with asthma exposed to budesonide. Ann Allergy Asthma Immunol. 2005;95:566–570.
ACOG Committee Opinion No. 577: Understanding and using the U.S. selected practice recommendations for contraceptive use, 2013. Obstet Gynecol. 2013;122:1132–1133.
Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol. 2005;74:119–131.
Banholzer ML, Buergin H, Wandel C, et al. Clinical trial considerations on male contraception and collection of pregnancy information from female partners. J Transl Med. 2012;10:129.
Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38:90–96.
National Institute for Health Care and Excellence. Long-acting reversible contraception (update). NICE Clinical Guidline 30 (Issued October 2005). London: NICE; 2014.
Parotti C, Ng EW, Wyszynski DF. Contraception methods in drug labeling. Drug Inform J. 2012;46:320–328.
Author information
Authors and Affiliations
Corresponding author
Additional information
Author Note
The opinions in this article are the personal views of the authors and do not reflect an official position of Amgen Inc, the Federal Agency for Medicines and Health Products, the Federal Institute for Drugs and Medical Devices, or of any European Medicines Agency committee or working party.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Stewart, J., Breslin, W.J., Beyer, B.K. et al. Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring. Ther Innov Regul Sci 50, 155–168 (2016). https://doi.org/10.1177/2168479015608415
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479015608415